REV3L and head and neck squamous cell carcinoma: A previous cellular study has shown that the downregulation of DNA lesion bypass polymerase ζ (Pol ζ) in the head and neck squamous carcinoma cells sensitizes cells to cisplatin, and inhibition of hRev3 gene expression was suggested to be a potential clinical strategy to reducing resistance against cisplatin in HNSCC [56].